Compare Manchester United PLC (MANU) vs Nuvalent Inc (NUVL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Manchester United PLC vs Nuvalent Inc — how do they compare? Manchester United PLC trades at $22.57 (market cap $3.80B), while Nuvalent Inc trades at $123.96 (market cap $9.81B). The key difference: Nuvalent Inc is far larger — about 2.6× Manchester United PLC's market cap, and Manchester United PLC pays a 1.26% dividend while Nuvalent Inc pays none. Which is the better fit depends on your goals.
| MANU | NUVL | |
|---|---|---|
Market Cap | $3.80B | $9.81B |
Sector | Media | Technology |
52-Week High | $23.53 | $123.96 |
52-Week Low | $15.10 | $72.16 |
Enterprise Value | $4.72B | $8.52B |
Dividend Yield | 1.26% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Manchester United (MANU) trades at $22.05, down 0.81% today, with a bullish technical signal from moving averages but mixed recent earnings performance. Revenue grew to $667M in 2025, yet net losses persist at -$33M. The company is advancing a new 100,000-seat stadium project, a key long-term growth driver, while securing Champions League qualification boosts future revenue prospects.
Outlook hinges on stadium development execution and sustained sporting success to drive profitability. Risks include high debt levels and inconsistent earnings. Analysts are cautiously optimistic with 40% buy ratings, but investors should monitor cash flow trends amid significant capital expenditures.
Nuvalent (NUVL) trades at $123.96, unchanged on the day, with a bullish technical signal from moving averages but overbought oscillators. The company reported a net loss of $425.38 million for 2025 and negative cash flow from operations. Recent news is dominated by GSK's proposed acquisition of Nuvalent for $124 per share, announced in June 2026, which is under investigation by multiple law firms for fairness to shareholders.
The investment outlook is heavily influenced by the pending acquisition. While analyst consensus shows no sell ratings, the stock price is near the offer price, limiting upside. Key risks include the deal's completion and the company's ongoing losses. The primary opportunity is the acquisition premium, but fundamental challenges persist absent the deal.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Manchester United PLC
Manchester United PLC operates a professional football club together with related and ancillary activities. The company manages the soccer team and all affiliated club activities of the Manchester United Football Club, which includes the media network, foundation, fan zone, news, sports features, and team merchandise. Manchester United is based in England. The company has three principal sectors from which most of the revenue is generated, including Commercial, Broadcasting, and Matchday.
Read more on MANU →About Nuvalent Inc
Nuvalent, Inc. is a clinical-stage oncology company focused on creating precisely targeted therapies for patients with cancers driven by specific gene mutations. The company leverages a deep understanding of structural biology and medicinal chemistry to design novel small-molecule kinase inhibitors to overcome resistance mechanisms in advanced solid tumors. Nuvalent is committed to developing its pipeline of candidates to address high unmet needs in the treatment of various cancers.
Read more on NUVL →
